Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Curr Eye Res. 2014 Jan 8;39(6):604–610. doi: 10.3109/02713683.2013.859275

Figure 6.

Figure 6

Co- and pre-treatment human corneal epithelial cells with lacritin increases cellular metabolic activity. Treating (Fig. 6A) CRL-11515 cells and (Fig. 6B) primary HCE cells with 0.004% BAK significantly reduced cellular metabolic activity (†P < 0.001 vs. control; n = 5). Simultaneous administration of 0.004% BAK and 1 nM lacritin significantly increased cellular metabolic activity by 10% (*P < 0.05 vs. BAK; n = 5). Pre-treatment of HCE cells with 1 nM lacritin increased cellular metabolic activity by 12% compared to BAK treatment alone (**P < 0.01 vs. BAK; n = 5). BAK = BAK for 1 min. BAK+L = BAK and lacritin for 1 min. L24h/BAK = Pre-incubation with lacritin for 24 hours, followed by BAK treatment for 1 min.

HHS Vulnerability Disclosure